On 6 September 2022, Fresenius Kabi announced that they had received approval from the US Food and Drug Administration (FDA) for their pegfilgrastim biosimilar, Stimufend (pegfilgrastim-fpgk).
FDA approves biosimilar pegfilgrastim Stimufend
Biosimilars/News | Posted 07/10/2022 0
Stimufend is produced by Fresenius Kabi, the generics unit of German healthcare giant Fresenius. The drug is a biosimilar of Amgen’s Neulasta (pegfilgrastim), a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy 
Stimufend is Fresenius Kabi’s first approved US biosimilar. It is a supportive care medicine for patients with non-myeloid cancer. It stimulates the growth of certain white blood cells, which are essential to prevent or fight infections, a common life-threatening risk in patients receiving myelosuppressive chemotherapy.
The approval for Stimufend (pegfilgrastim) is based on a review of a comprehensive data package and a totality of evidence that demonstrated a high degree of similarity with the reference product. No clinically meaningful differences in safety and immunogenicity were observed.
Stimufend received the European Commission’s (EC) marketing authorization in early 2022  and Fresenius Kabi intends to launch its pegfilgrastim biosimilar in a pre-filled syringe in Europe in the fall.
‘The FDA approval of pegfilgrastim biosimilar is an important step to better support the treatment experience and clinical outcomes of cancer patients in the United States’, according to Dr Michael Schönhofen, Fresenius Kabi’s Chief Operating Officer.
FDA has approved Amneal’s pegfilgrastim biosimilar, Fylnetra (pegfilgrastim-pbbk), in May 2022 .
More recently, Fresenius Kabi has submitted an application to FDA of its proposed tocilizumab biosimilar (MSB11456) on 1 August 2022 .
Totality of evidence for biosimilar pegfilgrastim-ziextenzo
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View the latest headline article: La FDA aprueba el biosimilar pegfilgrastim Stimufend
Browse the news in the Latin American Forum!
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Ver el último artículo de cabecera: La FDA aprueba el biosimilar pegfilgrastim Stimufend
!Explore las noticias en el Foro Latinoamericano!
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of teriparatide and pegfilgrastim biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Oct 7]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-teriparatide-and-pegfilgrastim-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves pegfilgrastim and rituximab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Oct 7]. Available from: www.gabionline.net/biosimilars/news/fda-approves-pegfilgrastim-and-rituximab-biosimilars
3. GaBI Online - Generics and Biosimilars Initiative. FDA accepts application for tocilizumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Oct 7]. Available from: www.gabionline.net/biosimilars/news/fda-accepts-application-for-tocilizumab-biosimilar
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
Source: Fresenius Kabi